michigan glp-1 vomiting class action Professor Ana Santos Rutschman weighed in on recent lawsuits alleging popular drugs can cause serious injuries and how these cases influence public trust, the market and risk warnings for these medications The FDA just announced there’s

The compounders argue a shortage still exists because the FDA acknowledged that there may still be intermittent and limited localized supply disruptions as the products move through the supply chain, while Novo has stated that supply constraints may still continue

Investment may be shifting away from rare diseases and niche therapies

Carroll, MD, co-founder and chief medical director of GLPrelief, and founder of BeSlimMD in Maitland, FL, who said that many times the what makes people stop taking GLP-1 drugs once they start is not the needle its how the medication makes them feel, and what it costs

However, CMS required plan sponsor participants to include all of their enhanced alternative plans and 90% of their enrollment in basic plans

doi: 10.1055/s-0031-1271777 49 Ben NasrMUsuelliVDellepianeSSeelamAJFiorentinoTVDAddioFet al

Pfeffer MA, Claggett B, Diaz R, Dickstein K, Gerstein HC, Kober LV, et al